Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis

被引:6
作者
Law, Jeanna Wallenta [1 ]
Campbell, Alicyn [2 ]
Weller, Colin [2 ]
Johanson, Colden [1 ]
Broome, Ronda [1 ]
Piault, Elisabeth [2 ]
Izano, Monika [1 ]
Schrag, Andrew [1 ]
Tran, Mary [1 ]
Brown, Thomas D. [1 ]
Kaplan, Henry G. [3 ]
机构
[1] Syapse, 303 2nd St,North Tower,Suite 500, San Francisco, CA 94107 USA
[2] AstraZeneca, 1800 Concord Pike, Wilmington, DE 19850 USA
[3] Swedish Canc Inst, 1221 Madison St, Seattle, WA 98104 USA
关键词
Metastatic breast cancer; HER2-directed therapy; Interstitial lung disease; Real-world; Epidemiology; RADIATION PNEUMONITIS; HER2;
D O I
10.1007/s10549-022-06738-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Using real-world data, interstitial lung disease (ILD) prevalence before and after HER2-directed therapy was estimated. Potential ILD risk factors in patients receiving HER2-directed therapy for metastatic breast cancer (mBC) were evaluated. Methods Adults with HER2-directed therapy for mBC initiated between September 25, 1998, and February 22, 2020 were, included. ILD was defined broadly as one or more of 64 lung conditions. Patients were followed until incident ILD, death, last contact, or study end. Results In total, 533 patients were identified with median age at mBC of 57, 51% had de novo mBC, 43% were ever smokers, 30% had lung metastases, 9% had thoracic radiation, 6% had chronic obstructive pulmonary disease, and 16% had prevalent ILD. ILD cumulative incidence at one year was 9% (95% CI 6%, 12%), with a median follow-up of 23 months. Smoking (HR 2.2, 95% CI 1.1, 4.8) and Black/African-American race (HR 3.4, 95% CI 1.6, 7.5) were significantly associated with ILD; HRs for preexisting lung conditions (HR 1.8, 95% CI 0.9, 3.8) and thoracic radiation (HR 2.3, 95% CI 0.8, 7.1) were not statistically significant. Prevalent ILD was associated with 13-fold greater occurrence of incident ILD. 85% of patients with prevalent or incident ILD were symptomatic. Conclusions This real-world population of patients with mBC had a high prevalence of ILD prior to HER2-directed therapy, reflecting the multifactorial causation of interstitial lung changes. The cumulative incidence of ILD in patients receiving HER2-directed therapy for mBC augments prior reports. Symptomatic presentation suggests an opportunity for early intervention.
引用
收藏
页码:603 / 611
页数:9
相关论文
共 23 条
  • [1] Clinical relevance of radiation pneumonitis in breast cancers
    Agrawal, Sushma
    [J]. SOUTH ASIAN JOURNAL OF CANCER, 2013, 2 (01) : 19 - 20
  • [2] Radiation pneumonitis in breast cancer patients treated with taxanes: Does sequential radiation therapy lower the risk?
    Beal, K
    Hudis, C
    Norton, L
    Wagman, R
    McCormick, B
    [J]. BREAST JOURNAL, 2005, 11 (05) : 317 - 320
  • [3] Recognizing Radiation Therapy-related Complications in the Chest
    Benveniste, Marcelo F.
    Gomez, Daniel
    Carter, Brett W.
    Cuellar, Sonia L. Betancourt
    Shroff, Girish S.
    Benveniste, Ana Paula A.
    Odisio, Erika G.
    Marom, Edith M.
    [J]. RADIOGRAPHICS, 2019, 39 (02) : 344 - 366
  • [4] Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature
    Bielopolski, Dana
    Evron, Ella
    Moreh-Rahav, Osnat
    Landes, Michal
    Stemmer, Salomon M.
    Salamon, Francis
    [J]. JOURNAL OF CHEMOTHERAPY, 2017, 29 (02) : 113 - 117
  • [5] Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey
    Cosgrove, Gregory P.
    Bianchi, Pauline
    Danese, Sherry
    Lederer, David J.
    [J]. BMC PULMONARY MEDICINE, 2018, 18
  • [6] Towards personalized treatment for early stage HER2-positive breast cancer
    Goutsouliak, Kristina
    Veeraraghavan, Jamunarani
    Sethunath, Vidyalakshmi
    De Angelis, Carmine
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Schiff, Rachel
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (04) : 233 - 250
  • [7] Heterogeneity in Unclassifiable Interstitial Lung Disease A Systematic Review and Meta-Analysis
    Guler, Sabina A.
    Ellison, Kina
    Algamdi, Mohmmed
    Collard, Harold R.
    Ryerson, Christopher J.
    [J]. ANNALS OF THE AMERICAN THORACIC SOCIETY, 2018, 15 (07) : 854 - 863
  • [8] Gutierrez C, 2011, ARCH PATHOL LAB MED, V135, P55, DOI 10.1043/2010-0454-RAR.1
  • [9] Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
    Hackshaw, Michelle D.
    Danysh, Heather E.
    Singh, Jasmeet
    Ritchey, Mary E.
    Ladner, Amy
    Taitt, Corina
    Camidge, D. Ross
    Iwata, Hiroji
    Powell, Charles A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 23 - 39
  • [10] Analysis of Time-to-onset and Onset-pattern of Interstitial Lung Disease after the Administration of Monoclonal Antibody Agents
    Komada, Fusao
    Nakayama, Yuko
    Takara, Kohji
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2018, 138 (12): : 1587 - 1594